LabCorp licenses NASH test for clinical research

By Maggie Lynch

- Last updated on GMT

(Image: Getty/omgimages)
(Image: Getty/omgimages)

Related tags Clinical research CRO regulatory approval Clinical development facility

LabCorp’s Covance has signed an agreement which it will use Genfit’s diagnostic test to identify and characterize patients.

Genfit has developed a non-invasive test for non-alcoholic steatohepatitis (NASH) using its blood-based biomarker test.

Covance, the drug development business of LabCorp, will validate the test’s use for identification and characterization of patients, and to generate biological insights on the pathogenesis of NASH. 

NIS4, Genfit’s test, used samples from 687 patients from two different cohorts to discover and internally validate the test, a spokesperson from Genfit told us. Through the agreement, the companies may be positioned to expand access of NIS4 to clinical research.

Currently, there are no extensively validated non-invasive diagnostic tests for NASH that address the evolving disease and therapeutic implications.

Through the partnership, LabCorp will distribute the test to clinical research facilities. Genfit will aim to release the test as a laboratory developed test (LDT) as early as 2019 for clinical research.

The Genfit spokesperson told us the goal of the partnership is “to provide an approved solution for routine clinical care that could be performed by any specialist.”

Genfit said it aims to submit a diagnostic test package for regulatory approval by 2020 in the US and Europe.

“Our ambition at this stage is much broader, with a solution designed to help all NASH patients, including those who will be identified as not needing drug therapy,”​ the spokesperson explained. “So not only will the diagnostic kit potentially improve the patient journey, help providers in identifying and managing patients, but we believe it will also allow researchers to collect essential data on NASH, and hopefully improve the understanding of its complex mechanisms.”

Financial terms for the agreement were not disclosed

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Related suppliers

Follow us


View more